Cumberland Pharmaceuticals
CPIX
23 hedge funds and large institutions have $28.6M invested in Cumberland Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.23% less ownership
Funds ownership: 32.11% → 31.88% (-0.23%)
15% less funds holding
Funds holding: 27 → 23 (-4)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
39% less capital inflows, than outflows
Capital inflows: $565K | Capital outflows: $920K
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$317K |
| 2 |
Ariel Investments
Chicago,
Illinois
|
+$115K |
| 3 |
BlueCrest Capital Management
St Helier,
Jersey
|
+$63.3K |
| 4 |
Renaissance Technologies
New York
|
+$54.5K |
| 5 |
Morgan Stanley
New York
|
+$8.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stonepine Capital Management
Bend,
Oregon
|
-$646K |
| 2 |
BlackRock
New York
|
-$134K |
| 3 |
Delta Asset Management
Memphis,
Tennessee
|
-$72K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$23.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$15.7K |
CPIX Hedge Fund Activity: Q1 2019 in Review
23 of the 4,634 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q1 2019, worth a combined $28.6M — down 6.2% from $30.5M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CPIX and 1 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $317K. The largest seller was Stonepine Capital Management, cutting an estimated $646K.
- 23 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q1 2019, down from 27 in Q4 2018.
- Funds reported $28.6M of Cumberland Pharmaceuticals stock for Q1 2019, down 6.2% quarter-over-quarter.
- 1 fund opened new Cumberland Pharmaceuticals positions in Q1 2019 and 5 closed out, a net change of -4 holders.
- The largest Cumberland Pharmaceuticals buyer in Q1 2019 was Vanguard Group, an estimated $317K added.
- The largest Cumberland Pharmaceuticals seller in Q1 2019 was Stonepine Capital Management, an estimated $646K sold.
Based on aggregated 13F filings for Q1 2019.